Cohort 4 Early Data Shows 32.4% ORR by Investigator Assessment at 5.3 Months of Median Study Follow up Cohort 2 Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up and ...
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced positive results from cohort 4 of the ...
SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech (ONCY) ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today ...
(RTTNews) - Corvus Pharmaceuticals, Inc. (CRVS) is set to announce new data today from Cohort 4 of its ongoing placebo-controlled Phase 1 clinical trial evaluating Soquelitinib. Soquelitinib, the ...
75% of soquelitinib patients achieved EASI 75, 25% achieved EASI 90 and 33% achieved IGA 0/1 Cohort 1-4 have demonstrated positive safety and efficacy results in patients who have received prior ...
Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results